TLSA
Tiziana Life Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$0.90
−4.77%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -74.7%
- EBIT
- -26.2%
- EPS
- -79.4%
- Free cash flow
- -60.7%
- Operating cash flow
- -60.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +12.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -9.4%
- EBIT
- -33.8%
- Net income
- -55.4%
- EPS
- -45.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026